PROCEPT BioRobotics Corporation
PRCT
$59.03
$1.412.45%
Weiss Ratings | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Fair | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.19 | |||
Price History | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -2.56% | |||
30-Day Total Return | -18.58% | |||
60-Day Total Return | -33.99% | |||
90-Day Total Return | -36.04% | |||
Year to Date Total Return | -29.02% | |||
1-Year Total Return | 24.04% | |||
2-Year Total Return | 85.69% | |||
3-Year Total Return | 101.47% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -44.49% | |||
52-Week Low % Change | 26.47% | |||
Price | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $103.81 | |||
52-Week Low Price | $45.56 | |||
52-Week Low Price (Date) | Apr 04, 2024 | |||
52-Week High Price (Date) | Nov 11, 2024 | |||
Valuation | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 3.16B | |||
Enterprise Value | 2.91B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -1.76 | |||
Earnings Per Share Growth | -21.67% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 13.82 | |||
Price/Book (Q) | 7.84 | |||
Enterprise Value/Revenue (TTM) | 12.95 | |||
Price | $59.03 | |||
Enterprise Value/EBITDA (TTM) | -31.81 | |||
Enterprise Value/EBIT | -30.09 | |||
Market Cap Category | Mid Cap | |||
Dividends and Shares | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 53.84M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 650 232 7200 | |||
Address | 150 Baytech Drive San Jose, CA 95134 | |||
Website | www.procept-biorobotics.com | |||
Country | United States | |||
Year Founded | 2007 | |||
Profitability | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -43.03% | |||
Profit Margin | -40.71% | |||
Management Effectiveness | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -12.86% | |||
Return on Equity | -- | |||
Income Statement | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 224.50M | |||
Total Revenue (TTM) | 224.50M | |||
Revenue Per Share | $4.17 | |||
Gross Profit (TTM) | 137.10M | |||
EBITDA (TTM) | -91.38M | |||
EBIT (TTM) | -96.61M | |||
Net Income (TTM) | -91.41M | |||
Net Income Avl. to Common (TTM) | -91.41M | |||
Total Revenue Growth (Q YOY) | 56.57% | |||
Earnings Growth (Q YOY) | 31.44% | |||
EPS Diluted (TTM) | -1.76 | |||
EPS Diluted Growth (Q YOY) | 35.59% | |||
Balance Sheet | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 333.73M | |||
Cash Per Share (Q) | $6.20 | |||
Total Current Assets (Q) | 481.84M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 402.22M | |||
Current Ratio (Q) | 9.069 | |||
Book Value Per Share (Q) | $7.35 | |||
Total Assets (Q) | 534.02M | |||
Total Current Liabilities (Q) | 53.13M | |||
Total Debt (Q) | 82.25M | |||
Total Liabilities (Q) | 131.80M | |||
Total Common Equity (Q) | 402.22M | |||
Cash Flow | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -4.41M | |||
Cash from Financing (TTM) | 180.13M | |||
Net Change in Cash (TTM) | 76.50M | |||
Levered Free Cash Flow (TTM) | -77.39M | |||
Cash from Operations (TTM) | -99.21M | |||